In summary, our findings suggest that the combination of sintilimab and anlotinib delivers meaningful clinical activity with acceptable toxicity in driver‐negative advanced NSCLC progressing after first‐line PD‐1 blockade, and thus warrants consideration as an additional therapeutic choice. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.